LONDON (Reuters) - The European Medicines Agency said on Thursday that warnings about liver injury should be added to the product information for Biogen Idec Inc (BIIB.O: Quote, Profile, Research) and Elan Corp Plc's (ELN.I: Quote, Profile, Research) multiple sclerosis drug Tysabri.
